Becton, Dickinson and Company (BDX) Analyst Ratings & Price Targets

Becton, Dickinson and Company

BDX · NYSE

Analyst Consensus

Hold

16 analysts

$183

Current

—

Low

$195

Average

—

High

Average target implies +6.60% versus the current price.

Analyst Ratings Synthesis

Consensus is Hold, with all 16 tracked analysts in that category. The only stated target statistic is a $175 mean, versus $170.12 at the supplied week's end, putting the consensus target $4.88 higher; low and high targets are unavailable, so target clustering and dispersion cannot be measured. The evidence names no individual analysts or firms, highest or lowest target, or rating changes. It also records no upward or downward revisions during the week. The substantive disagreement therefore cannot be attributed to specific analysts; the available tension is between modest mean-target upside and the unchanged Hold consensus.

Rating Actions

No individual rating actions have been captured for BDXyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Countdown to Becton Dickinson (BDX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPSZacks
Uncertain

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BARCLAYS CAPITA

CITIGROUP

CO FORECST

EDWARD JONES

EVERCORE ISI

JEFFERIES & CO.

JP MORGAN SECUR

MORGAN STANLEY

PIPER SANDLER

RAYMOND JAMES

STIFEL NICOLAUS

TD COWEN

WELLS FARGO SEC

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: BDX
Type: Stock
Sector: Health Care
Industry: Surgical & Medical Instruments & Apparatus
Exchange: NYSE

BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare.

Key Issues

Bullish view

Revenue increased to $21.8 billion in FY2025 from $20.2 billion in FY2024, and the upcoming quarter is receiving detailed estimate scrutiny from Zacks. That creates a potential foundation for stronger results if operating metrics improve.

Bearish view

Net income remained at $1.7 billion in both fiscal years despite the revenue increase. The supplied evidence provides no indication that profitability is accelerating.

Analyst Consensus

See all

Hold

16 analysts

$183

Current

—

Low

$195

Average

—

High

Average target implies +6.60% versus the current price.

Earnings History

BeatMissNo estimate

Becton, Dickinson and Company

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers